research Delta‐6 desaturase knockout mouse illustrates previously undocumented pathology
Lack of certain fatty acids causes skin, immune, and fertility issues in mice.
Search
for
Sort by
Research
990-1000 / 1000+ resultsresearch Co-administration of Glyphaea brevis and Monodora myristica Modulates Finasteride-induced Oxidative Stress and Haematological Alterations
Glyphaea brevis and Monodora myristica can protect against finasteride's harmful effects on blood and oxidative stress in male rats.
research Histone deacetylase inhibitors promote neurosteroid‐mediated cell differentiation and enhance serotonin‐stimulated brain‐derived neurotrophic factor gene expression in rat C6 glioma cells
HDAC inhibitors help brain cells grow and improve brain function.
research Formulation of a film-coated dutasteride tablet bioequivalent to a soft gelatin capsule (Avodart®): Effect of γ-cyclodextrin and solubilizers
Created tablet similar to Avodart using γ-cyclodextrin and solubilizers.
research Abstract 5561: 20(S)-Protopanaxadiol-aglycone downregulates full-length and ligand-independent splice variants of androgen receptor
20(S)-Protopanaxadiol-aglycone may help prevent and treat prostate cancer by reducing androgen receptor activity.
research The influence of secoisolariciresinol diglusoside on non-emasculated rat in BPH
SDG helps reduce BPH effects in rats.
research Coordination of force-generating actin-based modules stabilizes and remodels membranes in vivo
Actin filaments help stabilize and reshape cell membranes.
research Upcycling Eggshell Matrix for Sustainable Production of Glycosaminoglycans
Eggshells can be used to sustainably and cheaply produce important compounds like glycosaminoglycans.
research PO-105 Exercise regulates HMGB1 / TLR4 / NF- κ B pathway by H2S to improve OJ intestinal injury
Aerobic exercise helps protect the intestines by improving their barrier function.
research Non-clinical safety evaluation and risk assessment to human of aleglitazar, a dual PPAR α/γ agonist, and its major human metabolite
Aleglitazar and its major metabolite are safe enough to proceed to Phase 3 clinical trials.